Therefore, multiple medical centers worldwide have used the SGLT2 inhibitor empagliflozin as a potential treatment option for neutropenia and neutrophil dysfunction in patients with GSD Ib since 2020 [14–17]. This evidence concerns the gene SLC5A2 and neutropenia.